Mansi C, Savarino V, Vigneri S, Sciabà L, Perilli D, Mele M R, Celle G
Department of Internal Medicine--Gastroenterology Unit, University of Genoa, Italy.
Aliment Pharmacol Ther. 1995 Apr;9(2):185-9. doi: 10.1111/j.1365-2036.1995.tb00369.x.
Abnormal gall-bladder motility has been reported in diabetics. The objective was to evaluate the effect of chronic D2-dopamine receptor inhibition on gall-bladder emptying in diabetic patients.
Under double-blind placebo-controlled conditions and according to a crossover design, patients were randomly assigned to receive either 4 weeks treatment with levosulpiride 25 mg t.d.s. or 4 weeks treatment with placebo, with an interval of 15 days. Twenty-three consecutive long-standing, insulin-treated diabetics with autonomic neuropathy were studied.
At the beginning of the study and after levosulpiride or placebo treatment, gall-bladder emptying was measured ultrasonically by evaluating the gall-bladder volume in basal conditions and every 15 min for 90 min after the ingestion of a standard meal. Statistical analysis of the results was performed by means of analysis of variance.
Levosulpiride treatment reduced the basal mean gall-bladder volume from 21.6 +/- 2.3 to 18.6 +/- 2.3 mL (P < 0.05). Furthermore, the residual gall-bladder volume (9.3 +/- 1.4 mL) was significantly reduced compared to the corresponding pre-treatment volume (14.6 +/- 1.5 mL (P < 0.05). In placebo-treated patients, no significant differences were observed in gall-bladder volumes before and after treatment.
These results show that chronic oral administration of the D2-dopamine antagonist levosulpiride has a significant effect on gall-bladder motility in diabetic patients.
据报道,糖尿病患者存在胆囊运动异常。本研究旨在评估长期抑制D2 - 多巴胺受体对糖尿病患者胆囊排空的影响。
在双盲安慰剂对照条件下,按照交叉设计,将患者随机分为两组,分别接受为期4周的25 mg左旋舒必利每日三次治疗或4周的安慰剂治疗,中间间隔15天。对23例连续的长期接受胰岛素治疗的自主神经病变糖尿病患者进行了研究。
在研究开始时以及左旋舒必利或安慰剂治疗后,通过超声评估基础状态下的胆囊体积以及摄入标准餐后每15分钟一次,共90分钟的胆囊体积,以此来测量胆囊排空情况。采用方差分析对结果进行统计学分析。
左旋舒必利治疗使基础平均胆囊体积从21.6±2.3 mL降至18.6±2.3 mL(P < 0.05)。此外,残余胆囊体积(9.3±1.4 mL)与相应的治疗前体积(14.6±1.5 mL)相比显著减小(P < 0.05)。在接受安慰剂治疗的患者中,治疗前后胆囊体积未观察到显著差异。
这些结果表明,长期口服D2 - 多巴胺拮抗剂左旋舒必利对糖尿病患者的胆囊运动有显著影响。